Management of Opioid Poisoning

Initial Assessment and Management

• The American Heart Association recommends that for patients in respiratory arrest, rescue breathing or bag-mask ventilation should be maintained until spontaneous breathing returns, and standard BLS/ALS measures should continue if spontaneous breathing does not occur 1, 2
• For patients suspected to be in cardiac arrest, standard resuscitative measures should take priority over naloxone administration, with focus on high-quality CPR 1, 3
• Emergency response systems should be activated immediately without delay while awaiting the patient's response to naloxone 1, 2
• For patients with suspected opioid overdose who have a definite pulse but no normal breathing or only gasping, naloxone should be administered in addition to standard BLS/ALS care 1, 2

Naloxone Administration

• Naloxone, a μ-opioid receptor antagonist, can restore spontaneous respirations and protective airway reflexes in patients with opioid overdose 1, 3
• Potential adverse effects of naloxone include precipitating opioid withdrawal; sudden-onset pulmonary edema can occur but responds to positive pressure ventilation 1, 3

Post-Naloxone Management

• After return of spontaneous breathing, patients should be observed in a healthcare setting until the risk of recurrent opioid toxicity is low and vital signs have normalized 4, 5
• If recurrent opioid toxicity develops, repeated small doses or an infusion of naloxone can be beneficial 4, 5
• The duration of action of naloxone may be shorter than the respiratory depressive effect of the opioid, particularly with long-acting formulations, requiring repeat doses or a naloxone infusion 4, 5
• Observation periods should be tailored to the type of opioid involved - shorter periods may be adequate for fentanyl, morphine, or heroin overdose, while longer periods are needed for long-acting or sustained-release opioids 4, 5

Special Considerations

• Non-response to naloxone may indicate polysubstance overdose involving non-opioid substances, such as benzodiazepines or xylazine 6

Community and Lay Responder Training

• It is reasonable for lay rescuers to receive training in responding to opioid overdose, including provision of naloxone 5, 3
• Educating patients with opioid use disorder and their close contacts improves risk awareness, overdose recognition, willingness to administer naloxone, and attitudes toward calling emergency services 3
• Training that includes skills practice leads to improved clinical performance compared to interventions without skills practice 5

Common Pitfalls to Avoid

• Delaying activation of emergency response systems while awaiting response to naloxone 1, 2
• Failing to consider co-ingestions that may require specific management approaches 6
• Discharging patients too early after naloxone administration, especially with long-acting opioid ingestions 4, 5

Naloxone-Associated Pulmonary Edema

Risk and Incidence

• The CDC notes that serious adverse effects like pulmonary edema are rare at doses consistent with labeled use for opioid overdose 7

Clinical Considerations

• The American Heart Association emphasizes using the lowest effective dose to minimize withdrawal symptoms and associated complications, although the strength of this evidence is not specified 7

Management of Opioid Poisoning with Naloxone

Naloxone Administration and Dosage

• The American Heart Association recommends titrating naloxone to restore respiratory effort, not consciousness, with a goal of reversal of respiratory depression and restoration of protective airway reflexes, not full arousal, in patients with suspected opioid overdose 8
• Initial naloxone doses are 0.2-2 mg IV/IO/IM for adults, 0.1 mg/kg for pediatric patients, and 2-4 mg intranasally, repeated every 2-3 minutes as needed, to minimize withdrawal symptoms in opioid-dependent patients 8
• If recurrent opioid toxicity develops, administer repeated small doses or a continuous infusion of naloxone, with a maintenance infusion of two-thirds of the waking dose per hour, to reverse respiratory depression and restore protective airway reflexes 8

Special Considerations for Polysubstance Overdose

• The American Heart Association suggests that non-response to naloxone strongly suggests polysubstance overdose involving non-opioid substances, such as benzodiazepines or xylazine, and recommends administering naloxone first for respiratory depression or respiratory arrest in cases of suspected combined opioid and benzodiazepine poisoning 8
• Naloxone should never be withheld when opioid overdose is suspected, even if benzodiazepine co-ingestion is present, due to the prevalence of opioid-adulterated illicit drugs 9

Management of Naloxone-Induced Pulmonary Edema

Immediate Management

• The American Heart Association recommends positive pressure ventilation as the primary treatment for naloxone-induced pulmonary edema, which responds readily to this intervention 10, 11, 12, 13
• Non-invasive positive pressure ventilation (CPAP/BiPAP) can be used if the patient can protect their airway 13
• The cornerstone of treatment is positive pressure ventilation, which effectively manages this sudden-onset complication even when severe 10, 11, 12, 13

Critical Pitfalls to Avoid

• The American Heart Association guidelines state that positive pressure ventilation should not be withheld or delayed when pulmonary edema develops, as this is the definitive treatment 10, 11, 12, 13
• Patients who develop naloxone-induced pulmonary edema should not be discharged prematurely after naloxone administration, and should be observed until respiratory status and vital signs normalize 11, 13

Duration of Monitoring

• Patients who develop naloxone-induced pulmonary edema require continued observation in a healthcare setting until the risk of recurrent opioid toxicity is low and vital signs have normalized 11, 13

Guideline Recommendations for Opioid Poisoning Management (Circulation 2023)

Immediate Priorities: Airway, Breathing, and Emergency Activation

• Airway management and ventilatory support must be performed before any naloxone administration in patients with suspected opioid poisoning. 14
• Emergency response systems should be activated immediately, without waiting for the patient’s response to any intervention. 14
• Rescue breathing or bag‑mask ventilation should be started without delay; this is the primary life‑saving action. 14
• Ventilatory support is continued until spontaneous breathing returns; if it does not, standard BLS/ALS measures are maintained indefinitely. 14

Naloxone Administration: Indications and Priorities

• In patients with a palpable pulse but absent or inadequate breathing, naloxone is given in addition to—not instead of—ventilatory support. 14
• For cardiac arrest (no pulse), high‑quality CPR (compressions + ventilation) takes absolute priority over naloxone. 14
• No studies have shown improved outcomes from naloxone use during cardiac arrest; routine administration in this setting is not recommended. 14
• Naloxone may be administered during cardiac arrest only if it does not delay or interrupt any component of high‑quality CPR. 14

Post‑Resuscitation Observation

• After the last naloxone dose, patients should be observed in a healthcare setting until the risk of recurrent opioid toxicity is low and vital signs are stable.
• Minimum observation periods:
  
  • Short‑acting opioids (e.g., fentanyl, morphine, heroin) – at least 2 hours.
  • Long‑acting or sustained‑release opioids – at least 6–8 hours. 14

Complications of Naloxone

• Abrupt reversal can precipitate opioid‑withdrawal syndrome (agitation, nausea, vomiting, sweating, circulatory stress). 14
• Sudden‑onset pulmonary edema is rare but can be severe; it responds promptly to positive‑pressure ventilation (invasive or non‑invasive CPAP/BiPAP if the airway is protected). 14
• Rapid reversal may lead to cardiac arrhythmias. 14

Critical Pitfalls to Avoid

• Do not delay emergency activation while awaiting a response to naloxone; the clinical condition may be non‑opioid‑related. 14
• Do not prioritize naloxone over airway management and ventilatory support in respiratory arrest. 14
• Do not use naloxone as a first‑line treatment in cardiac arrest, as it has no proven benefit in that setting. 14